Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate– Full safety and immunogenicity results expected for end 2019 — Lyon, France – September 26th, 2019 – Osivax announced today that all participants have completed their final visit in the first-in-human clinical trial of OVX836 universal Influenza vaccine …
